TrialSignal
Clinical trial intelligence report
A Phase II Single-Arm Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07034391
Status
RECRUITING
Phase
PHASE2
Sponsor
China Medical University, China
Executive brief
Investment-Ready Snapshot
This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07034391
Indication
Non-Small Cell Lung Cancer
Modality
small molecule
Target
denosumab combined anti-PD-1 inhibitor with chemotherapy
Intervention
denosumab combined anti-PD-1 inhibitor with chemotherapy
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.